Xcout Intel
Protagenic Therapeutics, Inc.new competitors & alternatives
The 12 closest competitors and alternatives to Protagenic Therapeutics, Inc.new among biotech companies — ranked by similarity to what Protagenic Therapeutics, Inc.new actually does, not by market-cap band.
Subscribe to see Protagenic Therapeutics, Inc.new’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Protagenic Therapeutics, Inc.new
Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress. Foremost among its investigational products is PT00114, a laboratory-synthesized version of the teneurin carboxy-terminal associated peptide. This compound functions by emulating an innate brain signaling peptide, known for its ability to temper exaggerated stress reactions. The company's headquarters are located in New York, New York.
Protagenic Therapeutics, Inc.new at a glance
Protagenic Therapeutics, Inc.new is a biotech company headquartered in New York, United States. It is publicly listed (PTIX) with a market capitalisation of $391,005. Xcout tracks 16 named people at Protagenic Therapeutics, Inc.new, including William Nichols Jr. (President).
Protagenic Therapeutics, Inc.new leadership
- William Nichols Jr.President
- Andrew SleeChief Development Officer
- Robert Benjamin SteinChief Medical Officer
- Garo H. ArmenExecutive Chairman
- Barrett EvansDirector
- Brian CorveseDirector
10 more named people on record for Protagenic Therapeutics, Inc.new, with roles, board committees and tenure — see the full roster →
Top 12 Protagenic Therapeutics, Inc.new competitors
Ranked by semantic similarity — how close each company is to Protagenic Therapeutics, Inc.new by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
ProJenX, Inc. is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City. The firm focuses on neuroscience, developing novel, brain-penetrant therapies targeting biologically defined motor neuron diseases such as ALS. It advances research programs aimed at addressing severe neurodegenerative conditions.
Biotechnology
Protagonist Therapeutics is a clinical-stage biopharmaceutical company headquartered at the Pacific Research Center in Newark, California, focused on peptide drug discovery.
Life Sciences (Therapeutics)
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
Biotechnology
AtaiBeckley Inc. has its corporate headquarters located in New York, USA. The biopharmaceutical company is on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments.
Similar biotech company
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
Similar biotech company
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Similar biotech company
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Similar biotech company
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Similar biotech company
Proximity Therapeutics, Inc. is a privately held biopharmaceutical and biotechnology company based in Cambridge, Massachusetts, founded in 2021. The neuro space company operates as a provider of biotechnology and develops next-generation medicines by controlling biological processes through proximity.
Biotechnology
ProteKt Therapeutics is a biotechnology company founded in 2014 and headquartered in Beni-Brak, Israel, that develops novel therapeutics focusing on the nervous system and cellular protection.
Biotechnology
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Biotechnology
Soleno Therapeutics Inc. is a company based in the United States, focused on the development of therapies. It operates as a Neurocrine Biosciences company, with its headquarters located at 100 Marine Parkway, Suite 400.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Protagenic Therapeutics, Inc.new and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Protagenic Therapeutics, Inc.newand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →